Efficacy of Therapy With PRP Injections Versus HA in Patients With Advanced Grade of GONArthrosis

Launched by CENTRE HOSPITALIER INTERCOMMUNAL DE TOULON LA SEYNE SUR MER · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two types of knee injections—Platelet Rich Plasma (PRP) and Hyaluronic Acid (HA)—in treating patients with advanced knee osteoarthritis, also known as gonarthrosis. Gonarthrosis is a painful condition that causes the cartilage in the knee to wear down, leading to discomfort and reduced mobility. The main goal of this research is to find out which injection works better to relieve pain and improve the quality of life for patients who can't have surgery.

To be eligible for this trial, participants must be at least 18 years old and have advanced knee osteoarthritis with a pain level of 3 or higher on a scale of 0 to 10. They should also have a body mass index (BMI) of less than 35 and be able to give consent to participate. Unfortunately, individuals who have taken certain medications recently or have specific medical conditions may not be able to join the study. If selected, participants can expect to receive one of the two types of injections and will be monitored for improvements in their symptoms. This trial is important because it aims to provide a better understanding of treatment options for patients who suffer from severe knee pain but are not candidates for surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years ;
• • 2. Advanced grade unilateral gonarthrosis ;
• • 3. Pain ≥ 3/10 on the visual analogue scale (VAS);
• • 4. Patient with a BMI \< 35
• • 5. Patient capable of giving consent prior to participation in the study;
• • 6. Affiliated or entitled under a social security scheme.
• Exclusion Criteria:
• • 1. Non-steroidal anti-inflammatory drugs or corticosteroids taken in the 7 days prior to inclusion;
• • 2. Local injection of hyaluronic acid in the 2 months prior to inclusion;
• • 3. Local injection of PRP within 2 years prior to inclusion;
• • 4. Local injection of corticosteroids within 5 months prior to inclusion;
• • 5. Current anticoagulant treatment that cannot be stopped for the duration of the study;
• • 6. Patient diagnosed with any type of cancer in the last 3 years;
• • 7. Pregnant women, women in labour or breast-feeding women;
• • 8. Patients under judicial protection (guardianship, curatorship, etc.) or safeguard of justice;
• • 9. Any other reason which, in the opinion of the investigator, could interfere with the evaluation of the study objectives.
• Secondary exclusion criteria:
• • 1. Unilateral grade III or IV gonarthrosis not confirmed on MRI.